AIDS Therapy

The Immune Response Corp. announces results from Remune trial

Published in AIDS Weekly, September 16th, 2002

Indicating for the first time in a clinical trial that Remune might give relief for HIV-infected patients from the adverse side-effects of antiretroviral therapies, The Immune Response Corp. (IMNR) announced results from an ongoing study by the Canadian HIV Trials Network (CTN-140 trial), which examined the effects of stopping HAART (highly active antiretroviral therapy) in adults with chronic HIV infection.

"With the growing number of studies indicating that HIV-infected patients are developing greater resistance and significant adverse side-effects to the battery of antiretroviral drugs available today, the results from this study suggest that treatment strategies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry